SeaStar Medical is sponsoring a KidneyBee Summit and an educational webinar to advance treatment of pediatric acute kidney injury. The KidneyBee Summit 2026 takes place at Children’s Hospital Colorado from July 14 to 16, bringing together nurses, advanced practice providers, and physicians to address systemic failures in recognizing pediatric kidney failure. The webinar, titled Rethinking Pediatric Sepsis-Associated AKI: What Clinicians Should Know About QUELIMMUNE, will be held on August 11, 2026, and will focus on the company’s QUELIMMUNE therapy, a first-in-class device that neutralizes overactive immune cells to stop destructive hyperinflammation. Data from clinical trials showed a 77% survival rate with QUELIMMUNE versus standard of care, representing an approximate 50% reduction in loss of life compared to historical data. Real-world data from the QUELIMMUNE SAVE Registry showed a 76% survival rate at Day 28 and Day 60 in the first 21 pediatric patients, with no device-related adverse events.
SeaStar Medical Holding CorporationSponsoring summit and webinar to advance QUELIMMUNE therapy, with clinical data showing 77% survival rate and 50% reduction in loss of life.